LianBio Research and Development Expense
LianBio (LIANY) reported Research and Development Expense of $9.02 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-11-13
- LianBio research and development expense for the quarter ending 2023-09-30 was $9.02M, a 9.20% increase year-over-year.
- LianBio research and development expense for the quarter ending 2023-06-30 was $9.45M, a 66.93% decline year-over-year.
- LianBio research and development expense for the quarter ending 2023-03-31 was $10.83M, a 12.15% decline year-over-year.
- LianBio research and development expense for the quarter ending 2022-12-31 was $10.58M, a 38.19% increase year-over-year.
- LianBio research and development expense for fiscal 2022 was $59.76M, a 62.35% decline from fiscal 2021.
- LianBio research and development expense for fiscal 2021 was $158.69M, a 31.28% increase from fiscal 2020.
- LianBio research and development expense for fiscal 2020 was $120.89M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $9.02M 10-Q · filed 2023-11-13 | $18.47M derived: sum of 2 quarters · filed 2023-11-13 | $29.30M 10-Q · filed 2023-11-13 | $39.88M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $9.45M 10-Q · filed 2023-08-14 | $20.29M 10-Q · filed 2023-08-14 | $30.86M derived: sum of 3 quarters · filed 2023-08-14 | $39.12M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | $10.83M 10-Q · filed 2023-05-11 | $21.41M derived: sum of 2 quarters · filed 2023-05-11 | $29.67M derived: sum of 3 quarters · filed 2023-11-13 | $58.26M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $10.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $18.84M derived: sum of 2 quarters · filed 2023-11-13 | $47.43M derived: sum of 3 quarters · filed 2023-11-13 | $59.76M 10-K · filed 2023-03-28 |
| 2022-09-30 | $8.26M 10-Q · filed 2023-11-13 | $36.85M derived: sum of 2 quarters · filed 2023-11-13 | $49.18M 10-Q · filed 2023-11-13 | $56.83M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $28.59M 10-Q · filed 2023-08-14 | $40.92M 10-Q · filed 2023-08-14 | $48.57M derived: sum of 3 quarters · filed 2023-08-14 | $53.23M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $12.33M 10-Q · filed 2023-05-11 | $19.98M derived: sum of 2 quarters · filed 2023-05-11 | $24.64M derived: sum of 3 quarters · filed 2023-05-11 | $117.67M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $12.31M derived: sum of 2 quarters · filed 2023-03-28 | $105.34M derived: sum of 3 quarters · filed 2023-03-28 | $158.69M 10-K · filed 2023-03-28 |
| 2021-09-30 | $4.66M 10-Q · filed 2022-11-10 | $97.69M derived: sum of 2 quarters · filed 2022-11-10 | $151.04M 10-Q · filed 2022-11-10 | $153.75M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $93.03M 10-Q · filed 2022-08-11 | $146.38M 10-Q · filed 2022-08-11 | $149.09M derived: sum of 3 quarters · filed 2022-08-11 | $266.01M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $53.35M 10-Q · filed 2022-05-12 | $56.06M derived: sum of 2 quarters · filed 2022-05-12 | $172.98M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $2.71M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $119.63M derived: sum of 2 quarters · filed 2022-03-31 | $120.89M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $116.92M 10-Q/A · filed 2022-01-10 | $118.17M 10-Q/A · filed 2022-01-10 |